PSA MONITORING DURING TESTOSTERONE REPLACEMENT THERAPY: LOW LONGTERM RISK OF PROSTATE CANCER WITH IMPROVED OPPORTUNITY FOR CURE

An abstract of the study by Feneley and Carruthers on PSA monitoring during testosterone replacement therapy is presented. Results of the study indicate that changes in PSA in response to testosterone replacement appear overall to be not significant, irrespective of hormone formulation. The risk of...

Full description

Saved in:
Bibliographic Details
Published in:The aging male 2004-03, Vol.7 (1), p.30
Main Authors: Feneley, M R, Carruthers, M E
Format: Article
Language:English
Subjects:
Androgens
Hormone replacement therapy
Medical disorders
Medical treatment
Men
Prostate cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An abstract of the study by Feneley and Carruthers on PSA monitoring during testosterone replacement therapy is presented. Results of the study indicate that changes in PSA in response to testosterone replacement appear overall to be not significant, irrespective of hormone formulation. The risk of prostate cancer in a pre-screened and carefully monitored population treated for androgen deficiency appears low, and treatment can be offered early.
ISSN:1368-5538
1473-0790